A UCSD center that's been facilitating Covid-19 clinical research gets $55M from NIH to boost translational work

Amber Tong

A team at the University of California San Diego that’s been facilitating studies on the frontlines of Covid-19 has received a $54.7 million grant from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A UCSD center that's been facilitating Covid-19 clinical research gets $55M from NIH to boost translational work

Amber Tong

Sign up to read this article for free.

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm

A UCSD cen­ter that's been fa­cil­i­tat­ing Covid-19 clin­i­cal re­search gets $55M from NIH to boost trans­la­tion­al work

Amber Tong

Sign up to read this article for free.

more like this

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

De­spite mixed da­ta in Alzheimer's ag­i­ta­tion, Ax­some will still seek FDA ap­proval

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

A UCSD center that's been facilitating Covid-19 clinical research gets $55M from NIH to boost translational work

Ideaya inks ADC deal with $75M upfront; Amylyx, Gubra to develop long-acting GLP-1

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

FDA approves subcutaneous version of Bristol Myers' Opdivo

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

WuXi AppTec will sell cell and gene therapy business to private equity firm